Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Vitrolife AB (publ): Interim report Q2, 2025: Strong performance across Consumables

Vitrolife
Download the release

Second quarter

  • Sales of SEK 871 (941) million, a flat growth in local currencies and a 7% decrease in SEK, due to a significant currency impact of -8%. Organic growth in local currencies excluding discontinued business was 3%.
  • Sales per region, in local currencies was -3% in EMEA, +5% excluding discontinued business, +5% in Americas and 0% in APAC.
  • Sales per product group, in local currencies excluding discontinued business was +9% in Consumables, -6% in Technologies and +3% in Genetics.
  • Sales per product group, in local currencies was +5% in Consumables, -8% in Technologies and 0% in Genetics.
  • Gross margin decreased to 58.0% (59.9) also negatively impacted by currency.
  • Earnings before depreciation and amortisation (EBITDA) decreased to SEK 243 (327) million, resulting in an EBITDA margin of 27.8% (34.7), significantly impacted by negative currency effect.
  • Operating cash flow amounted to SEK 151 million (236).
  • Net income was SEK 100 (143) million, resulting in earnings per share of SEK 0.74 (1.06).
  • Vitrolife AB (publ) acquired a leading stake in AutoIVF.

First half year

  • Sales of SEK 1,714 (1,782) million, a flat growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -4%. Organic growth in local currencies excluding discontinued business was 3%.
  • Sales per region, in local currencies was +2% in EMEA, +10% excluding discontinued business, +7% in Americas and -8% in APAC.
  • Sales per product group, in local currencies excluding discontinued business was +7% in Consumables, -6% in Technologies and +4% in Genetics.
  • Sales per product group, in local currencies was +4% in Consumables, -7% in Technologies and +1% in Genetics.
  • Gross margin decreased to 57.7% (58.6) also negatively impacted by currency.
  • Earnings before depreciation and amortisation (EBITDA) decreased to SEK 500 (600) million, resulting in an EBITDA margin of 29.2% (33.6), significantly impacted by negative currency effect.
  • Operating cash flow amounted to SEK 220 million (434).
  • Net income was SEK 199 (258) million, resulting in earnings per share of SEK 1.48 (1.91).

Gothenburg, July 17, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-07-2025 08:00 CET.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.